Abstract |
A new high-pressure liquid chromatographic method was developed for the simultaneous determination of rubidazone and daunorubicin in human plasma at concentrations as low as 60 ng/ml. Clinical toxicity and the stability of rubidazone were studied in nine patients with advanced solid tumors. Rubidazone was administered by i.v. infusion over 1 hr on a single day every 4 weeks. Moderate leukopenia was the dose-limiting toxicity in four of six patients treated at 150 mg sq/m. Assay of rubidazone in plasma samples obtained after administration of rubidazone showed that the drug was stable for at least 7 hr.
|
Authors | J S Kovach, M M Ames, M L Sternad, M J O'Connell |
Journal | Cancer research
(Cancer Res)
Vol. 39
Issue 3
Pg. 823-8
(Mar 1979)
ISSN: 0008-5472 [Print] United States |
PMID | 427770
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Adult
- Chromatography, High Pressure Liquid
- Daunorubicin
(analogs & derivatives, blood, toxicity)
- Drug Evaluation
- Female
- Humans
- Infusions, Parenteral
- Leukopenia
(chemically induced)
- Male
- Middle Aged
- Neoplasms
(drug therapy)
- Time Factors
|